[Dimethyl double nucleic acid sustained-release tablets are initially good]_action_effect

[Dimethyl double nucleic acid sustained-release tablets are initially good]_action_effect

For diabetic patients, the control of daily blood glucose requires the use of some drugs.

Among them, metformaldehyde sustained-release tablets are a kind of drug that can stimulate the secretion of insulin. For patients with type 2 diabetes, the effect is relatively ideal.

But if we go to buy dimethyl dna nucleic acid sustained-release tablets, we will find many different dimethyl dna nucleic acid sustained-release tablets.

So, first of all, is metformin sustained-release tablets better?

Erjiashuangshen Sustained-release Tablets are initially good1, Erjiashuangshen Sustained-release Tablets is first and foremost. Cardiovascular Dishuangshen sustained-release tablets are suitable for patients with type 2 diabetes who cannot be well controlled with diet and exercise alone.

This product can be used alone or in combination with sulfonylureas or insulin.

If it is necessary to explain that the brand of chlorhexidine sustained release tablets is good, in fact, as long as the chlorhexidine sustained release tablets delivered through the distance production process are trustworthy, everyone can avoid too much.

Finally, the author recommends that people who need metformin hydrochloride sustained-release tablets should pay attention to purchasing at a pharmacy from a distance.

After buying home, you should carefully check the instructions for use.

2. When is it better to take metformin extended-release tablets? Metformin hydrochloride extended-release tablets are recommended to be taken with food or after meals. Metformin hydrochloride is a hypoglycemic agent that improves cardiovascular tolerance in patients with type 2 diabetes.Sex, reducing basal and postprandial blood sugar effects.

The mechanism of action of metformin hydrochloride and other types of oral anti-glycemic drugs can reduce the production of liver sugar, reduce the absorption of sugar in the intestine, and increase the sensitivity of insulin by increasing the absorption and utilization of glucose, and sulfonylureas.The difference is that metformin does not cause hypoglycemia in patients with type 2 diabetes or normal blood sugar.

After metformin hydrochloride treatment, insulin secretion remained unchanged, while reducing fasting insulin levels and daily plasma insulin levels.

3, Metformin sustained-release tablets have replaced Metformin hydrochloride sustained-release tablets Ames test, mouse lymphocyte gene mutation test, human lymphocyte chromosome aberration test and mouse micronucleus test result substitution.

Reproductive toxicity: Male and female rats were supplemented with metformin at a dose of up to 600mg / kg / day (equivalent to 3 times the human clinically recommended large daily dose when converted by body), and there was no effect on fertility.

The rabbits were given dimethylbisoxazole hydrochloride at a dose of up to 600 mg / kg / day (equivalent to 2 and 6 times the human daily recommended large daily dose when converted by the body), and there was no teratogenic effect.

Pharmacological action of metformin hydrochloride sustained-release tablets The pharmacological action mechanism of metformin hydrochloride sustained-release tablets is different from that of other oral hypoglycemic drugs.

Metformic acid reduces the glycogenogenic effect of the liver, reduces the absorption of glucose in the small intestine, and improves insulin sensitivity by increasing the uptake and utilization of glucose by expanded tissues.

Unlike thioureas, metformin does not produce hypoglycemia or cause hyperinsulinemia in patients with type 2 diabetes and normal people.

Treatment with metformin, although it may reduce fasting insulin levels and plasma insulin response throughout the day, usually there is no change in insulin secretion.

The mechanism of hypoglycemic effect of metformin extended-release tablets may be: 1. Increase the sensitivity of surrounding tissues to insulin and increase insulin-mediated glucose utilization.

2. Increase the utilization of glucose by non-insulin-dependent tissues, such as brain, blood cells, renal medulla, itself, and skin.

3, inhibit liver gluconeogenesis and reduce liver glucose output.

4. Inhibition of glucose uptake by intestinal wall cells.

5. Inhibit cholesterol biosynthesis and storage, reduce blood triglycerides and total cholesterol levels.

Unlike diabetes, this product does not promote metabolites, has no significant effect on reducing blood sugar in normal people, and generally does not cause hypoglycemia when used alone for type II diabetes.